These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35351234)

  • 1. WHO target product profiles for TB preventive treatment.
    Den Boon S; Lienhardt C; Zignol M; Schwartzman K; Arinaminpathy N; Campbell JR; Nahid P; Penazzato M; Menzies D; Vesga JF; Oxlade O; Churchyard G; Merle CS; Kasaeva T; Falzon D
    Int J Tuberc Lung Dis; 2022 Apr; 26(4):302-309. PubMed ID: 35351234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
    Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
    PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis.
    Vesga JF; Lienhardt C; Nsengiyumva P; Campbell JR; Oxlade O; den Boon S; Falzon D; Schwartzman K; Churchyard G; Arinaminpathy N
    BMC Med; 2022 May; 20(1):182. PubMed ID: 35581650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.
    Kendall EA; Shrestha S; Cohen T; Nuermberger E; Dooley KE; Gonzalez-Angulo L; Churchyard GJ; Nahid P; Rich ML; Bansbach C; Forissier T; Lienhardt C; Dowdy DW
    PLoS Med; 2017 Jan; 14(1):e1002202. PubMed ID: 28045934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updating the WHO target product profile for next-generation Mycobacterium tuberculosis drug susceptibility testing at peripheral centres.
    MacLean EL; Miotto P; González Angulo L; Chiacchiaretta M; Walker TM; Casenghi M; Rodrigues C; Rodwell TC; Supply P; André E; Kohli M; Ruhwald M; Cirillo DM; Ismail N; Zignol M
    PLOS Glob Public Health; 2023; 3(3):e0001754. PubMed ID: 37000774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis.
    Uppal A; Rahman S; Campbell JR; Oxlade O; Menzies D
    PLoS Med; 2021 Sep; 18(9):e1003712. PubMed ID: 34520463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urgent need to address the slow scale-up of TB preventive treatment in the WHO South-East Asia Region.
    Satyanarayana S; Bhatia V; Mandal PP; Kanchar A; Falzon D; Sharma M
    Int J Tuberc Lung Dis; 2021 May; 25(5):382-387. PubMed ID: 33977906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
    Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
    Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential impact of preventive therapy against tuberculosis in the WHO South-East Asian Region: a modelling approach.
    Mandal S; Bhatia V; Sharma M; Mandal PP; Arinaminpathy N
    BMC Med; 2020 Jul; 18(1):163. PubMed ID: 32684164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis.
    Yanes-Lane M; Ortiz-Brizuela E; Campbell JR; Benedetti A; Churchyard G; Oxlade O; Menzies D
    PLoS Med; 2021 Sep; 18(9):e1003738. PubMed ID: 34520459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial: Updates from the World Health Organization (WHO) on Global Treatment Recommendations for Drug-Susceptible and Multidrug-Resistant Tuberculosis.
    Parums DV
    Med Sci Monit; 2021 Aug; 27():e934292. PubMed ID: 34366429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada.
    Romanowski K; Chiang LY; Roth DZ; Krajden M; Tang P; Cook VJ; Johnston JC
    BMC Infect Dis; 2017 Sep; 17(1):604. PubMed ID: 28870175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control.
    Matteelli A; Migliori GB; Cirillo D; Centis R; Girard E; Raviglion M
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):857-71. PubMed ID: 17914919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidance for the Evaluation of Tuberculosis Diagnostics That Meet the World Health Organization (WHO) Target Product Profiles: An Introduction to WHO Process and Study Design Principles.
    Denkinger CM; Schumacher SG; Gilpin C; Korobitsyn A; Wells WA; Pai M; Leeflang M; Steingart KR; Bulterys M; Schünemann H; Glaziou P; Weyer K
    J Infect Dis; 2019 Oct; 220(220 Suppl 3):S91-S98. PubMed ID: 31593596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.